• Our Professionals
  • Our Work
  • Our Insights
  • Firm
  • Careers
  • Tools
Finnegan
404 Not Found

Not Found

The requested URL /esi/auxiliary-nav.html was not found on this server.

Additionally, a 404 Not Found error was encountered while trying to use an ErrorDocument to handle the request.

AIA Blog

Two New Precedential PTAB Decisions Applying the Fintiv Factors

December 22, 2020

By Amanda K. Murphy, Ph.D.

Edited by Kevin D. Rodkey

On Thursday, December 17, 2020, the Board designated portions of two decisions applying the Fintiv factors as precedential:  Sotera Wireless, Inc. v. Masimo Corp., IPR2020-01019, Paper 12 (Dec. 1, 2020) (precedential as to § II.A) and Snap, Inc. v. SRK Technology LLC, IPR2020-00820, Paper 15 (Oct. 21, 2020) (precedential as to § II.A). 

The Fintiv factors, set forth below, guide the Board’s analysis regarding whether to deny institution under 35 U.S.C. § 314(a) in view of a related litigation:

  1. whether the court granted a stay or evidence exists that one may be granted if a proceeding is instituted;
  2. proximity of the court’s trial date to the Board’s projected statutory deadline for a final written decision;
  3. investment in the parallel proceeding by the court and the parties;
  4. overlap between issues raised in the petition and in the parallel proceeding;
  5. whether the petitioner and the defendant in the parallel proceeding are the same party; and
  6. other circumstances that impact the Board’s exercise of discretion, including the merits.

In Sotera Wireless, the Board noted that the petitioner’s broad stipulation not to pursue in district court any ground that it raised, or reasonably could have raised, in the IPR “weighs strongly in favor of not exercising discretion to deny institution.” The Sotera petition was filed approximately two weeks before the one-year time bar under 35 U.S.C. § 315(b).  At the time of institution, infringement and invalidity contentions had been served in district court, but fact discovery was still ongoing, and trial was set to begin around the time that the Board would issue its final written decision if the IPR was instituted.  The petitioner had filed a stipulation in the district court stating that, if the PTAB instituted the IPR, the petitioner would not pursue in the district court any ground that it raised or reasonably could have raised in the IPR.  The petitioner had also filed a motion to stay, but the district court had not yet ruled on the motion.  Applying a “holistic review” of the Fintiv factors, including (1) that the petition timing was reasonable in view of the number of patents and challenged claims in this and petitioner’s related petitions, (2) the relatively limited investment in the parallel proceeding to date, and (3) the minimal potential overlap between the two proceedings in view of petitioner’s stipulation, the Board declined to deny institution under § 314(a).

In Snap, Inc., the Board noted that a district court stay that would remain in place until a final written decision issued in the IPR “weighed strongly against exercising discretion to deny institution.”  In this case, at the time the petition was filed, preliminary contentions and claim construction positions had been exchanged and initial discovery had begun in the district court, but the court had not yet issued any substantive orders and had stayed the case pending either a denial of institution or a final written decision in the IPR.  Taking a “holistic view” of the Fintiv factors, the Board declined to deny institution under § 314(a), noting (1) the stay in the parallel district court proceeding, (2) the early stages of that parallel proceeding prior to the stay being granted, and (3) the lack of overlap between the invalidity contentions in the district court proceeding and the challenges raised in the petition.

Tags

Patent Trial and Appeal Board (PTAB), 35 U.S.C. § 314(a), 35 U.S.C. § 315(b)

Related Practices

Patent Litigation

Appeals

Post-Grant Proceedings

IPR, PGR, and CBM

Related Industries

Life Sciences

Medical Device and Diagnostics

Contacts

Amanda_Murphy
Amanda K. Murphy, Ph.D.
Partner
Washington, D.C.
+1 202 408 4114
Email
Kevin_Rodkey
Kevin D. Rodkey
Partner
Atlanta, GA
+1 404 653 6484
Email

Copyright © 2020 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

Best Practices in Intellectual Property 2021

June 14-15, 2021

Tel Aviv

Webinar

Patent Claim and Specification Drafting and Prosecution

March 11, 2021

Webinar

Webinar

Patent Year in Review: Key Decisions, Trends, and Strategies

February 25, 2021

Webinar

Webinar

Patenting Pharmaceutical Drug Formulations: Withstanding Litigation and PTAB Challenges

February 16, 2021

Webinar

Webinar

Building Company Value With Cybersecurity Patents

February 8, 2021

Webinar

Webinar

Comparison of EPO Oppositions and USPTO PTAB Proceedings

January 28, 2021

Webinar

Conference

PTAB Bar Association Virtual Thought Leader Summit 2021

January 28, 2021

Virtual

European IP Blog

Subject-Matter Eligibility at the EPO: Life Sciences

January 25, 2021

Prosecution First Blog

Patentee’s Success Story in a Hatch-Waxman Litigation Case

January 22, 2021

Due to international data regulations, we’ve recently updated our privacy policy. Click here to read our privacy policy in full.

We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.

  • Privacy
  • Disclaimer
  • EEO Statement

© 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP